This study is in progress, not accepting new patients
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Irvine UCSF
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Idorsia Pharmaceuticals Ltd.
- ID
- NCT03737214
- Phase
- Phase 3 Fabry Disease Research Study
- Study Type
- Interventional
- Participants
- Expecting 107 study participants
- Last Updated